Modified INOvent for delivery of inhaled nitric oxide during cardiac MRI.

dc.contributor.author

Devendra, Ganesh P

dc.contributor.author

Hart, Stephen A

dc.contributor.author

Kim, Yuli Y

dc.contributor.author

Setser, Randy M

dc.contributor.author

Flamm, Scott D

dc.contributor.author

Krasuski, Richard A

dc.coverage.spatial

Netherlands

dc.date.accessioned

2015-12-03T17:46:52Z

dc.date.issued

2011-10

dc.description.abstract

BACKGROUND: The aim of this study was to assess the feasibility of delivering NO through a modified system to allow clearance of the magnetic field and thus compatibility with cardiac magnetic resonance (CMR). Nitric oxide (NO) is an inhalational, selective pulmonary vasodilator with a wide range of applications in a variety of disease states, including diseases that affect the right ventricle. Accurate assessment of dynamic changes in right ventricular function necessitates CMR; however, delivery of NO is only possible using equipment that is not magnetic resonance imaging (MRI) compatible (INOvent delivery system, Ohmeda, Inc., Madison, WI, USA). METHODS: The INOvent delivery system was modified by using 35 ft. of standard oxygen tubing to allow NO delivery through an electrical conduit and into the MRI suite. The concentrations of oxygen (O(2)), nitrogen dioxide (a harmful byproduct, NO(2)) and NO were measured in triplicate using the built-in electrochemical analyzer on the INOvent. After confirmation of safety, the system was used to administer drug to a patient x, and dynamic MRI measurements were performed. RESULTS: When the standard INOvent was set to administer 40 ppm of NO, the mean/standard deviation of gas delivered was as follows: NO: 42/0 ppm; NO(2): 0.3/0.1 ppm; and O(2): 93/0 ppm. In comparison, the gas delivery of the modified INOvent was follows: NO: 41/0 ppm; NO(2): 0.5/0 ppm; and O(2): 93.7/0.6 ppm. During administration to an index patient with severe pulmonic insufficiency (PI), a measurable reduction in PI was observed by CMR. CONCLUSIONS: Nitric oxide can be administered through 35 ft. of standard oxygen tubing without significantly affecting dose delivery. This technique has potential application in patients with right-sided structural heart disease for determination of dynamic physiological changes.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/21705165

dc.identifier

S0730-725X(11)00185-8

dc.identifier.eissn

1873-5894

dc.identifier.uri

https://hdl.handle.net/10161/11025

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Magn Reson Imaging

dc.relation.isversionof

10.1016/j.mri.2011.05.008

dc.subject

Adult

dc.subject

Diastole

dc.subject

Electrochemistry

dc.subject

Equipment Design

dc.subject

Heart Ventricles

dc.subject

Humans

dc.subject

Magnetic Fields

dc.subject

Magnetic Resonance Imaging

dc.subject

Male

dc.subject

Myocardium

dc.subject

Nitric Oxide

dc.subject

Oxygen

dc.subject

Pulmonary Valve

dc.subject

Systole

dc.subject

Tetralogy of Fallot

dc.subject

Time Factors

dc.title

Modified INOvent for delivery of inhaled nitric oxide during cardiac MRI.

dc.type

Journal article

duke.contributor.orcid

Krasuski, Richard A|0000-0003-3150-5215

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/21705165

pubs.begin-page

1145

pubs.end-page

1149

pubs.issue

8

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Cardiology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

29

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Modified Inovent.pdf
Size:
376.05 KB
Format:
Adobe Portable Document Format
Description:
Published version